nach oben

15.02.2024 | Review

Radionuclide Imaging of the Neuroanatomical and Neurochemical Substrate of Cognitive Decline in Parkinson’s Disease

verfasst von: Samuel Booth, Ji Hyun Ko

Erschienen in: Nuclear Medicine and Molecular Imaging

Einloggen, um Zugang zu erhalten

Abstract

Cognitive impairment is a frequent manifestation of Parkinson’s disease (PD), resulting in decrease in patients’ quality of life and increased societal and economic burden. However, cognitive decline in PD is highly heterogenous and the mechanisms are poorly understood. Radionuclide imaging techniques like positron emission tomography (PET) and single photon emission computed tomography (SPECT) have been used to investigate the neurochemical and neuroanatomical substrate of cognitive decline in PD. These techniques allow the assessment of different neurotransmitter systems, changes in brain glucose metabolism, proteinopathy, and neuroinflammation in vivo in PD patients. Here, we review current radionuclide imaging research on cognitive deficit in PD with a focus on predicting accelerating cognitive decline. This research could assist in the development of prognostic biomarkers for patient stratification and have utility in the development of ameliorative or disease-modifying therapies targeting cognitive deficit in PD.

Williams-Gray CH, Mason SL, Evans JR, Foltynie T, Brayne C, Robbins TW, et al. The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry. 2013;84:1258–64.PubMedCrossRef

Counsell C, Giuntoli C, Khan QI, Maple-Grødem J, Macleod AD. The incidence, baseline predictors, and outcomes of dementia in an incident cohort of Parkinson’s disease and controls. J Neurol. 2022;269:4288–98.PubMedPubMedCentralCrossRef

Fredericks D, Norton JC, Atchison C, Schoenhaus R, Pill MW. Parkinson’s disease and Parkinson’s disease psychosis: a perspective on the challenges, treatments, and economic burden. Fredericks D, editor. Am J Manag Care. 2017;23:S83–92.

Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord. 2019;34:180–98.PubMedPubMedCentralCrossRef

Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: movement disorder society task force guidelines. Mov Disord. 2012;27:349–56.PubMedPubMedCentralCrossRef

Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007;22:1689–707.PubMedCrossRef

Pedersen KF, Larsen JP, Tysnes OB, Alves G. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. JAMA Neurol. 2013;70:580–6.PubMedCrossRef

Domellöf ME, Ekman U, Forsgren L, Elgh E. Cognitive function in the early phase of Parkinson’s disease, a five-year follow-up. Acta Neurol Scand. 2015;132:79–88.PubMedCrossRef

Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010;75:1062–9.PubMedPubMedCentralCrossRef

10.

Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, et al. The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009;132:2958–69.PubMedCrossRef

11.

Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol. 2010;9:1200–13.PubMedCrossRef

12.

Kehagia AA, Barker RA, Robbins TW. Cognitive impairment in Parkinson’s disease: the dual syndrome hypothesis. Neurodegener Dis. 2012;11:79–92.PubMedCrossRef

13.

Fang C, Lv L, Mao S, Dong H, Liu B. Cognition deficits in Parkinson’s disease: mechanisms and treatment. Parkinsons Dis. 2020;2020:2076942.PubMedPubMedCentral

14.

Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease. N Engl J Med. 1988;318:876–80. https://doi.org/10.1056/NEJM198804073181402.CrossRefPubMed

15.

Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci. 1986;9:357–81.PubMedCrossRef

16.

Calabresi P, Picconi B, Tozzi A, Ghiglieri V, Di Filippo M. Direct and indirect pathways of basal ganglia: a critical reappraisal. Nat Neurosci. 2014;17:1022–30.PubMedCrossRef

17.

Cash R, Dennis T, L’Heureux R, Raisman R, Javoy-Agid F, Scatton B. Parkinson’s disease and dementia: norepinephrine and dopamine in locus ceruleus. Neurology. 1987;37:42–6.PubMedCrossRef

18.

Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol. 2003;60:337–41.PubMedCrossRef

19.

Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson’s disease. Brain Res. 1983;275:321–8.PubMedCrossRef

20.

Jellinger KA. Pathology of Parkinson’s disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol. 1991;14:153–97.PubMedCrossRef

21.

Surmeier DJ, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci. 2017;18:101–13.PubMedPubMedCentralCrossRef

22.

Kumakura Y, Cumming P. PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches. Neurosci. 2009;15:635–50.

23.

Kodaka F, Ito H, Kimura Y, Fujie S, Takano H, Fujiwara H, et al. Test-retest reproducibility of dopamine D2/3 receptor binding in human brain measured by PET with [11C]MNPA and [11C] raclopride. Eur J Nucl Med Mol Imaging. 2013;40:574–9.PubMedCrossRef

24.

Muslimović D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology. 2005;65:1239–45.PubMedCrossRef

25.

Owen AM. Cognitive dysfunction in Parkinson’s disease: the role of frontostriatal circuitry. Neuroscientist. 2004;10:525–37.PubMedCrossRef

26.

Nobili F, Campus C, Arnaldi D, De Carli F, Cabassi G, Brugnolo A, et al. Cognitive-nigrostriatal relationships in de novo, drug-naïve Parkinson’s disease patients: a [I-123]FP-CIT SPECT study. Mov Disord. 2010;25:35–43.PubMedCrossRef

27.

Ekman U, Eriksson J, Forsgren L, Mo SJ, Riklund K, Nyberg L. Functional brain activity and presynaptic dopamine uptake in patients with Parkinson’s disease and mild cognitive impairment: a cross-sectional study. Lancet Neurol. 2012;11:679–87. https://doi.org/10.1016/S1474-4422(12)70138-2.CrossRefPubMed

28.

Siepel FJ, Brønnick KS, Booij J, Ravina BM, Lebedev AV, Pereira JB, et al. Cognitive executive impairment and dopaminergic deficits in de novo Parkinson’s disease. Mov Disord. 2014;29:1802–8.PubMedCrossRef

29.

Pellecchia MT, Picillo M, Santangelo G, Longo K, Moccia M, Erro R, et al. Cognitive performances and DAT imaging in early Parkinson’s disease with mild cognitive impairment: a preliminary study. Acta Neurol Scand. 2015;131:275–81.PubMedCrossRef

30.

Schrag A, Siddiqui UF, Anastasiou Z, Weintraub D, Schott JM. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson’s disease: a cohort study. Lancet Neurol. 2017;16:66. https://doi.org/10.1016/S1474-4422(16)30328-3.CrossRefPubMed

31.

Christopher L, Marras C, Duff-Canning S, Koshimori Y, Chen R, Boileau I, et al. Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson’s disease with mild cognitive impairment. Brain. 2014;137:565–75.PubMedCrossRef

32.

Klein JC, Eggers C, Kalbe E, Weisenbach S, Hohmann C, Vollmar S, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology. 2010;74:885–92.PubMedCrossRef

33.

Candy JM, Perry RH, Perry EK, Irving D, Blessed G, Fairbairn AF, et al. Pathological changes in the nucleus of meynert in Alzheimer’s and Parkinson’s diseases. J Neurol Sci. 1983;59:277–89.PubMedCrossRef

34.

Liu AKL, Chang RCC, Pearce RKB, Gentleman SM. Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer’s and Parkinson’s disease. Acta Neuropathol. 2015;129:527–40.PubMedPubMedCentralCrossRef

35.

Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004;351:2509–18.PubMedCrossRef

36.

Fong TG, Inouye SK, Dai W, Press DZ, Alsop DC. Association cortex hypoperfusion in mild dementia with Lewy bodies: a potential indicator of cholinergic dysfunction? Brain Imaging Behav. 2011;5:25–35.PubMedPubMedCentralCrossRef

37.

Aghourian M, Legault-Denis C, Soucy J-P, Rosa-Neto P, Gauthier S, Kostikov A, et al. Quantification of brain cholinergic denervation in Alzheimer’s disease using PET imaging with [18F]-FEOBV. Mol Psychiatry. 2017;22:1531–8. https://doi.org/10.1038/mp.2017.183.CrossRefPubMed

38.

Kilbourn MR, Hockley B, Lee L, Sherman P, Quesada C, Frey KA, et al. Positron emission tomography imaging of (2R,3R)-5-[(18)F]fluoroethoxybenzovesamicol in rat and monkey brain: a radioligand for the vesicular acetylcholine transporter. Nucl Med Biol. 2009;36:489–93.PubMedPubMedCentralCrossRef

39.

van der Zee S, Muller MLTM, Kanel P, van Laar T, Bohnen NI. Cholinergic denervation patterns across cognitive domains in Parkinson’s disease. Mov Disord. 2020;36:1–10.

40.

van der Zee S, Kanel P, Gerritsen MJJ, Boertien JM, Slomp AC, Müller MLTM, et al. Altered cholinergic innervation in de novo Parkinson’s disease with and without cognitive impairment. Mov Disord. 2022;37:713–23. https://doi.org/10.1002/mds.28913.CrossRefPubMedPubMedCentral

41.

Schumacher J, Kanel P, Dyrba M, Storch A, Bohnen NI, Teipel S, et al. Structural and molecular cholinergic imaging markers of cognitive decline in Parkinson’s disease. Brain (London, Engl 1878). 2023;146:4964.

42.

Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology. 2005;65:1716–22.PubMedCrossRef

43.

Shimada H, Hirano S, Shinotoh H, Aotsuka A, Sato K, Tanaka N, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology. 2009;73:273–8.PubMedCrossRef

44.

Bohnen NI, Albin RL, Müller MLTM, Petrou M, Kotagal V, Koeppe RA, et al. Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of parkinson disease and evidence of interaction effects. JAMA Neurol. 2015;72:194–200.PubMedPubMedCentralCrossRef

45.

Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol. 2003;60:1745–8.PubMedCrossRef

46.

Kish SJ, Tong J, Hornykiewicz O, Rajput A, Chang LJ, Guttman M, et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson’s disease. Brain. 2008;131:120–31.PubMed

47.

Pagano G, Niccolini F, Fusar-Poli P, Politis M. Serotonin transporter in Parkinson’s disease: a meta-analysis of positron emission tomography studies. Ann Neurol. 2017;81:171–80.PubMedCrossRef

48.

Frouni I, Kwan C, Belliveau S, Huot P. Cognition and serotonin in Parkinson’s disease. Prog Brain Res. 2022;269:373–403.PubMedCrossRef

49.

Fenelon G. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain. 2000;123:733–45.PubMedCrossRef

50.

Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD, Sathyan A, et al. Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A. 2011;108:14968–73.ADSPubMedPubMedCentralCrossRef

51.

Sheline YI, West T, Yarasheski K, Swarm R, Jasielec MS, Fisher JR, et al. An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice. Sci Transl Med. 2014;6:236re4.PubMedPubMedCentral

52.

Irwin DJ, Lee VMY, Trojanowski JQ. Parkinson’s disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci. 2013;14:626–36.PubMedPubMedCentralCrossRef

53.

Compta Y, Parkkinen L, Kempster P, Selikhova M, Lashley T, Holton J, et al. The significance of [alpha]-synuclein, amyloid-[beta] and tau pathologies in Parkinson’s disease progression and related dementia. Neuro - Degener Dis. 2014;13:154–6.CrossRef

54.

Lee JC, Kim SJ, Hong S, Kim YS. Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers. Exp Mol Med. 2019;51:1–10. https://doi.org/10.1038/s12276-019-0250-2.CrossRefPubMedPubMedCentral

55.

Buongiorno M, Compta Y, Martí MJ. Amyloid-β and τ biomarkers in Parkinson’s disease-dementia. J Neurol Sci. 2011;310:25–30. https://doi.org/10.1016/j.jns.2011.06.046.CrossRefPubMed

56.

Siderowf A, Xie SX, Hurtig H, Weintraub D, Duda J, Chen-Plotkin A, et al. CSF amyloid β 1–42 predicts cognitive decline in Parkinson disease. Neurology. 2010;75:1055–61.PubMedPubMedCentralCrossRef

57.

Goldman JG, Andrews H, Amara A, Naito A, Alcalay RN, Shaw LM, et al. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: relationships among biomarkers and Parkinson’s disease Features. Mov Disord. 2018;33:282–8.PubMedCrossRef

58.

Jack CRJ, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539–47.PubMedPubMedCentralCrossRef

59.

Akhtar RS, Xie SX, Chen YJ, Rick J, Gross RG, Nasrallah IM, et al. Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. PLoS ONE. 2017;12:1–18.CrossRef

60.

Gomperts SN, Locascio JJ, Rentz D, Santarlasci A, Marquie M, Johnson KA, et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology. 2013;80:85–91.PubMedPubMedCentralCrossRef

61.

Jokinen P, Scheinin N, Aalto S, Någren K, Savisto N, Parkkola R, et al. [11C]PIB-, [18F]FDG-PET and MRI imaging in patients with Parkinson’s disease with and without dementia. Park Relat Disord. 2010;16:666–70. https://doi.org/10.1016/j.parkreldis.2010.08.021.CrossRef

62.

Campbell Meghan C, Markham Joanne M, Flores Hubert M, Hartlein Johanna J, Goate Alison O, Cairns Nigel S, et al. Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases. Neurology. 2013;81:520–7.PubMedPubMedCentralCrossRef

63.

Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, et al. Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry. 2008;79:1331–8.PubMedCrossRef

64.

Melzer TR, Stark MR, Keenan RJ, Myall DJ, Macaskill MR, Pitcher TL, et al. Beta amyloid deposition is not associated with cognitive impairment in Parkinson’s disease. Front Neurol. 2019;10:1–9. https://doi.org/10.3389/fneur.2019.00391

65.

Mihaescu AS, Valli M, Uribe C, Cirarda MD, Masellis M, Guerrero AG, et al. Beta amyloid deposition and cognitive decline in Parkinson ’ s disease : a study of the PPMI cohort. Mol Brain. 2022;1–13. https://doi.org/10.1186/s13041-022-00964-1

66.

Myers PS, O’Donnell JL, Jackson JJ, Lessov-Schlaggar CN, Miller RL, Foster ER, et al. Proteinopathy and longitudinal cognitive decline in Parkinson disease. Neurology. 2022;99:e66-76.PubMedPubMedCentralCrossRef

67.

Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, et al. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer’s disease and Parkinson’s disease. Proc Natl Acad Sci U S A. 2001;98:12245–50.ADSPubMedPubMedCentralCrossRef

68.

Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci Off J Soc Neurosci. 2010;30:7281–9.CrossRef

69.

Samudra N, Lane-Donovan C, VandeVrede L, Boxer AL. Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues. J Clin Invest. 2023;133. https://doi.org/10.1172/JCI168553

70.

Zhang X, Gao F, Wang D, Li C, Fu Y, He W, et al. Tau pathology in Parkinson’s disease. Front Neurol. 2018;9:809.PubMedPubMedCentralCrossRef

71.

Malpetti M, La JR, Rabinovici GD. Tau beats amyloid in predicting brain atrophy in Alzheimer disease: implications for prognosis and clinical trials. J Nucl Med. 2022;63:830–2.PubMedPubMedCentralCrossRef

72.

Marquié M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78(5):787–800. https://doi.org/10.1002/ana.24517

73.

Tian M, Civelek AC, Carrio I, Watanabe Y, Kang KW, Murakami K, et al. International consensus on the use of tau PET imaging agent (18)F-flortaucipir in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2022;49:895–904.PubMedPubMedCentralCrossRef

74.

Zhang J, Jin J, Su D, Feng T, Zhao H. Tau-PET imaging in Parkinson’s disease : a systematic review and meta-analysis. Front Neurol. 2023;14:1145939. https://doi.org/10.3389/fneuro.2023.1145939

75.

Hansen AK, Damholdt MF, Fedorova TD, Knudsen K, Parbo P, Ismail R, et al. In vivo cortical tau in Parkinson’s disease using 18F-AV-1451 positron emission tomography. Mov Disord. 2017;32:922–7.PubMedCrossRef

76.

Lee SH, Cho H, Choi JY, Lee JH, Ryu YH, Lee MS, Lyoo CH. Distinct patterns of amyloid-dependent tau accumulation in Lewy body diseases. Mov Disord. 2018;33(2):262–272. https://doi.org/10.1002/mds.27252

77.

Alzghool OM, van Dongen G, van de Giessen E, Schoonmade L, Beaino W. α-Synuclein radiotracer development and in vivo imaging: recent advancements and new perspectives. Mov Disord. 2022;37:936–48.PubMedPubMedCentralCrossRef

78.

González-Redondo R, García-García D, Clavero P, Gasca-Salas C, García-Eulate R, Zubieta JL, et al. Grey matter hypometabolism and atrophy in Parkinson’s disease with cognitive impairment: a two-step process. Brain. 2014;137:2356–67.PubMedPubMedCentralCrossRef

79.

Albrecht F, Ballarini T, Neumann J, Schroeter ML. FDG-PET hypometabolism is more sensitive than MRI atrophy in Parkinson’s disease: a whole-brain multimodal imaging meta-analysis. NeuroImage Clin. 2019;21:101594. https://doi.org/10.1016/j.nicl.2018.11.004.CrossRefPubMed

80.

Firbank MJ, Yarnall AJ, Lawson RA, Duncan GW, Khoo TK, Petrides GS, et al. Cerebral glucose metabolism and cognition in newly diagnosed Parkinson’s disease: ICICLE-PD study. J Neurol Neurosurg Psychiatry. 2017;88:310–6.PubMedCrossRef

81.

Bohnen N, Koeppe R, Minoshima S, Giordani B, Albin R, Frey K, et al. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med. 2011;52:848–55.PubMedCrossRef

82.

Bohnen NI, Minoshima S, Giordani B, Frey KA, Kuhl DE. Motor correlates of occipital glucose hypometabolism in Parkinson’s disease without dementia. Neurology. 1999 [cited 2020 Mar 27];52:541–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10025784

83.

Shoji Y, Nishio Y, Baba T, Uchiyama M, Yokoi K, Ishioka T, et al. Neural substrates of cognitive subtypes in Parkinson’s disease: a 3-year longitudinal study. PLoS One. 2014;9:e110547.ADSPubMedPubMedCentralCrossRef

84.

Garcia-Garcia D, Clavero P, Salas CG, Lamet I, Arbizu J, Gonzalez-Redondo R, et al. Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2012;39:1767–77.PubMedCrossRef

85.

Tang Y, Ge J, Liu F, Wu P, Guo S, Liu Z, et al. Cerebral metabolic differences associated with cognitive impairment in Parkinson’s disease. PLoS ONE. 2016;11:1–11.

86.

Blum D, la Fougère C, Pilotto A, Maetzler W, Berg D, Reimold M, et al. Hypermetabolism in the cerebellum and brainstem and cortical hypometabolism are independently associated with cognitive impairment in Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2018;45:2387–95.PubMedCrossRef

87.

Mihaescu AS, Masellis M, Graff-Guerrero A, Kim J, Criaud M, Cho SS, et al. Brain degeneration in Parkinson’s disease patients with cognitive decline: a coordinate-based meta-analysis. Brain Imaging Behav. 2019;13:1021–34.PubMedCrossRef

88.

Lyoo CH, Jeong Y, Ryu YH, Rinne JO, Lee MS. Cerebral glucose metabolism of Parkinson's disease patients with mild cognitive impairment. Eur Neurol. 2010;64(2):65–73. https://doi.org/10.1159/000315036

89.

Yong SW, Yoon JK, An YS, Lee PH. A comparison of cerebral glucose metabolism in Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies. Eur J Neurol. 2007;14:1357–62.PubMedCrossRef

90.

Liepelt I, Reimold M, Maetzler W, Godau J, Reischl G, Gaenslen A, et al. Cortical hypometabolism assessed by a metabolic ratio in Parkinson’s disease primarily reflects cognitive deterioration - [18F]FDG-PET. Mov Disord. 2009;24:1504–11.PubMedCrossRef

91.

Pagonabarraga J, Gómez-Ansón B, Rotger R, Llebaria G, García-Sánchez C, Pascual-Sedano B, et al. Spectroscopic changes associated with mild cognitive impairment and dementia in Parkinson’s disease. Dement Geriatr Cogn Disord. 2013;34:312–8.CrossRef

92.

Foo H, Mak E, Yong TT, Wen MC, Chander RJ, Au WL, et al. Progression of subcortical atrophy in mild Parkinson’s disease and its impact on cognition. Eur J Neurol. 2017;24:341–8.PubMedCrossRef

93.

Weil RS, Hsu JK, Darby RR, Soussand L, Fox MD. Neuroimaging in Parkinson’s disease dementia: connecting the dots. Brain Commun. 2019;1(1):fcz006. https://doi.org/10.1093/braincomms/fcz006

94.

Baba T, Hosokai Y, Nishio Y, Kikuchi A, Hirayama K, Suzuki K, et al. Longitudinal study of cognitive and cerebral metabolic changes in Parkinson’s disease. J Neurol Sci. 2017;372:288–93. https://doi.org/10.1016/j.jns.2016.11.068.CrossRefPubMed

95.

Demailly F, Tard C, Lenfant P, Semah F, Moreau C, Dujardin K. Hypometabolism in posterior and temporal areas of the brain is associated with cognitive decline in Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2015;42:S550–S550.

96.

Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D. Metabolic brain networks associated with cognitive function in Parkinson’s disease. Neuroimage. 2007;34:714–23.PubMedCrossRef

97.

Meles SK, Tang CC, Teune LK, Dierckx RA, Dhawan V, Mattis PJ, et al. Abnormal metabolic pattern associated with cognitive impairment in Parkinson’s disease: a validation study. J Cereb Blood Flow Metab. 2015;35:1478–84. https://doi.org/10.1038/jcbfm.2015.112.CrossRefPubMedPubMedCentral

98.

Mattis PJ, Niethammer M, Sako W, Tang CC, Nazem A, Gordon ML, et al. Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases. Neurology. 2016;87:1925–33.PubMedPubMedCentralCrossRef

99.

Grueso S, Viejo-Sobera R. Machine learning methods for predicting progression from mild cognitive impairment to Alzheimer’s disease dementia: a systematic review. Alzheimer’s Res Ther. 2021;13(1):162. https://doi.org/10.1186/s13195-021-00900-w

100.

Booth S, Park KW, Lee CS, Ko JH. Predicting cognitive decline in Parkinson’s disease using FDG-PET–based supervised learning. J Clin Invest. 2022;132:1–9.CrossRef

101.

Tang CC, Eidelberg D. Abnormal metabolic brain networks in Parkinson’s disease. From blackboard to bedside. Prog Brain Res. 2010;184:160–76.CrossRef

102.

Borghammer P, Jonsdottir KY, Cumming P, Ostergaard K, Vang K, Ashkanian M, et al. Normalization in PET group comparison studies—the importance of a valid reference region. Neuroimage. 2008;40:529–40.PubMedCrossRef

103.

Apostolova I, Lange C, Mäurer A, Suppa P, Spies L, Grothe MJ, et al. Hypermetabolism in the hippocampal formation of cognitively impaired patients indicates detrimental maladaptation. Neurobiol Aging. 2018;65:41–50.PubMedCrossRef

104.

Darby RR, Joutsa J, Fox MD. Network localization of heterogeneous neuroimaging findings. Brain. 2019;142:70–9.PubMedCrossRef

105.

Belloli S, Morari M, Murtaj V, Valtorta S, Moresco RM, Gilardi MC. Translation imaging in Parkinson’s disease: focus on neuroinflammation. Front Aging Neurosci. 2020;12:152.PubMedPubMedCentralCrossRef

106.

Guzman-Martinez L, Maccioni RB, Andrade V, Navarrete LP, Pastor MG, Ramos-Escobar N. Neuroinflammation as a common feature of neurodegenerative disorders. Front Pharmacol. 2019;10:1–17.CrossRef

107.

de Pablos RM, Herrera AJ, Espinosa-Oliva AM, Sarmiento M, Muñoz MF, Machado A, et al. Chronic stress enhances microglia activation and exacerbates death of nigral dopaminergic neurons under conditions of inflammation. J Neuroinflammation. 2014;11:34.PubMedPubMedCentralCrossRef

108.

George S, Rey NL, Tyson T, Esquibel C, Meyerdirk L, Schulz E, et al. Microglia affect α-synuclein cell-to-cell transfer in a mouse model of Parkinson’s disease. Mol Neurodegener. 2019;14:34.PubMedPubMedCentralCrossRef

109.

Croisier E, Moran LB, Dexter DT, Pearce RKB, Graeber MB. Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J Neuroinflammation. 2005;2:14.PubMedPubMedCentralCrossRef

110.

Sulzer D, Alcalay RN, Garretti F, Cote L, Kanter E, Agin-Liebes J, et al. T cells from patients with Parkinson’s disease recognize α-synuclein peptides. Nature. 2017;546:656–61.ADSPubMedPubMedCentralCrossRef

111.

Jain P, Chaney AM, Carlson ML, Jackson IM, Rao A, James ML. Neuroinflammation pet imaging: current opinion and future directions. J Nucl Med. 2020;61:1107–12.PubMedPubMedCentralCrossRef

112.

Dupont A-C, Largeau B, Santiago Ribeiro MJ, Guilloteau D, Tronel C, Arlicot N. Translocator protein-18 kDa (TSPO) positron emission tomography (PET) imaging and its clinical impact in neurodegenerative diseases. Int J Mol Sci. 2017;18:785.PubMedPubMedCentralCrossRef

113.

Fujita M, Kobayashi M, Ikawa M, Gunn RN, Rabiner EA, Owen DR, et al. Comparison of four 11C-labeled PET ligands to quantify translocator protein 18 kDa (TSPO) in human brain: (R)-PK11195, PBR28, DPA-713, and ER176-based on recent publications that measured specific-to-non-displaceable ratios. EJNMMI Res. 2017;7(1):84. https://doi.org/10.1186/s13550-017-0334-8

114.

Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis. 2006;21:404–12.PubMedCrossRef

115.

Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, et al. Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol. 2005;57:168–75.PubMedCrossRef

116.

Bartels AL, Willemsen ATM, Doorduin J, de Vries EFJ, Dierckx RA, Leenders KL. [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson’s disease? Parkinsonism Relat Disord. 2010;16:57–9.PubMedCrossRef

117.

Dodel R, Spottke A, Gerhard A, Reuss A, Reinecker S, Schimke N, et al. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord. 2010;25:97–107.PubMedCrossRef

118.

Jucaite A, Svenningsson P, Rinne JO, Cselényi Z, Varnäs K, Johnström P, et al. Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson’s disease. Brain. 2015;138:2687–700.PubMedCrossRef

119.

Terada T, Yokokura M, Yoshikawa E, Futatsubashi M, Kono S, Konishi T, et al. Extrastriatal spreading of microglial activation in Parkinson’s disease: a positron emission tomography study. Ann Nucl Med. 2016;30:579–87.PubMedCrossRef

120.

Iannaccone S, Cerami C, Alessio M, Garibotto V, Panzacchi A, Olivieri S, et al. In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson’s disease. Parkinsonism Relat Disord. 2013;19:47–52.PubMedCrossRef

121.

Edison P, Ahmed I, Fan Z, Hinz R, Gelosa G, Ray Chaudhuri K, et al. Microglia, amyloid, and glucose metabolism in Parkinson’s disease with and without dementia. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2013;38:938–49.CrossRef

122.

Fan Z, Aman Y, Ahmed I, Chetelat G, Landeau B, Ray Chaudhuri K, et al. Influence of microglial activation on neuronal function in Alzheimer’s and Parkinson’s disease dementia. Alzheimers Dement. 2015;11:608-21.e7.PubMedCrossRef

123.

Kouli A, Spindler LRB, Fryer TD, Hong YT, Malpetti M, Aigbirhio FI, et al. Neuroinflammation is linked to dementia risk in Parkinson’s disease. Brain. 2023;awad322. https://doi.org/10.1093/brain/awad322

124.

Katako A, Shelton P, Goertzen AL, Levin D, Bybel B, Aljuaid M, et al. Machine learning identified an Alzheimer’s disease-related FDG-PET pattern which is also expressed in Lewy body dementia and Parkinson’s disease dementia. Sci Rep. 2018;8:1–13. https://doi.org/10.1038/s41598-018-31653-6.CrossRef

125.

Choi H, Kim YK, Yoon EJ, Lee JY, Lee DS. Cognitive signature of brain FDG PET based on deep learning: domain transfer from Alzheimer’s disease to Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2020;47:403–12.PubMedCrossRef

Titel: Radionuclide Imaging of the Neuroanatomical and Neurochemical Substrate of Cognitive Decline in Parkinson’s Disease
verfasst von: Samuel Booth
Ji Hyun Ko
Publikationsdatum: 15.02.2024
Verlag: Springer Nature Singapore
Erschienen in: Nuclear Medicine and Molecular Imaging
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI: https://doi.org/10.1007/s13139-024-00842-9

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten